Sarepta Therapeutics (SRPT) Receivables (2010 - 2026)

Sarepta Therapeutics' Receivables history runs 17 years deep, the most recent figure standing at $531.2 million for Q1 2026.

• On a quarterly basis, Receivables fell 25.66% year-over-year to $531.2 million in Q1 2026; TTM through Mar 2026 was $531.2 million, a 25.66% decrease from a year earlier, with the FY2025 full-year figure at $502.3 million, down 21.09% from the prior year.
• Receivables rose to $531.2 million in Q1 2026 per SRPT's latest filing, from $502.3 million in the prior quarter.
• Across five years, Receivables topped out at $714.6 million in Q1 2025 and bottomed at $195.9 million in Q1 2022.
• The 5-year median for Receivables is $408.9 million (2024), against an average of $414.2 million.
• Across the five-year window, Receivables soared 74.76% in 2025 and decreased 25.66% in 2026, its largest moves.
• Year by year, Receivables stood at $256.4 million in 2022, then jumped by 67.75% to $430.1 million in 2023, then jumped by 48.01% to $636.6 million in 2024, then dropped by 21.09% to $502.3 million in 2025, then climbed by 5.75% to $531.2 million in 2026.
• Per Business Quant, the three latest SRPT Receivables figures stand at $531.2 million (Q1 2026), $502.3 million (Q4 2025), and $524.4 million (Q3 2025).